 | Up a level |
de Azambuja, E; Agostinetto, E; Procter, M; Eiger, D; Pondé, N; Guillaume, S; Parlier, D; Lambertini, M; Desmet, A; Caballero, C; Aguila, C; Jerusalem, G; Walshe, J M; Frank, E; Bines, J; Loibl, S; Piccart-Gebhart, M; Ewer, M S; Dent, S; Plummer, C; ... (2023). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO open, 8(1), p. 100772. BMJ 10.1016/j.esmoop.2022.100772
Hecht, J R; Raman, S S; Chan, A; Kalinsky, K; Baurain, J-F; Jimenez, M M; Garcia, M M; Berger, M D; Lauer, U M; Khattak, A; Carrato, A; Zhang, Y; Liu, K; Cha, E; Keegan, A; Bhatta, S; Strassburg, C P; Roohullah, A (2023). Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. ESMO open, 8(2), p. 100884. BMJ 10.1016/j.esmoop.2023.100884
de With, M; Sadlon, A; Cecchin, E; Haufroid, V; Thomas, F; Joerger, M; van Schaik, R H N; Mathijssen, R H J; Largiadèr, C R (2023). Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe. ESMO open, 8(2), p. 101197. BMJ 10.1016/j.esmoop.2023.101197
König, D; Savic Prince, S; Hayoz, S; Zens, P; Berezowska, S; Jochum, W; Stauffer, E; Braunersreuther, V; Trachsel, B; Thierstein, S; Mark, M; Schmid, S; Curioni-Fontecedro, A; Addeo, A; Opitz, I; Guckenberger, M; Früh, M; Betticher, D C; Ris, H-B; Stupp, R; ... (2023). Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14. ESMO open, 8(4), p. 101595. BMJ 10.1016/j.esmoop.2023.101595
Echle, A; Ghaffari Laleh, N; Quirke, P; Grabsch, H I; Muti, H S; Saldanha, O L; Brockmoeller, S F; van den Brandt, P A; Hutchins, G G A; Richman, S D; Horisberger, K; Galata, C; Ebert, M P; Eckardt, M; Boutros, M; Horst, D; Reissfelder, C; Alwers, E; Brinker, T J; Langer, R; ... (2022). Artificial intelligence for detection of microsatellite instability in colorectal cancer-a multicentric analysis of a pre-screening tool for clinical application. ESMO open, 7(2), p. 100400. BMJ 10.1016/j.esmoop.2022.100400
König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials. ESMO open, 7(2), p. 100455. Elsevier 10.1016/j.esmoop.2022.100455
Mark, M; Rusakiewicz, S; Früh, M; Hayoz, S; Grosso, F; Pless, M; Zucali, P; Ceresoli, G L; Maconi, A; Schneider, M; Froesch, P; Tarussio, D; Benedetti, F; Dagher, J; Kandalaft, L; von Moos, R; Tissot-Renaud, S; Schmid, S; Metaxas, Y (2022). Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study. ESMO open, 7(3), p. 100446. BMJ 10.1016/j.esmoop.2022.100446
König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. ESMO open, 7(3), p. 100494. Elsevier 10.1016/j.esmoop.2022.100494
Dafni, U; Soo, R A; Peters, S; Tsourti, Z; Zygoura, P; Vervita, K; Han, J-Y; De Castro, J; Coate, L; Früh, M; Hashemi, S M S; Nadal, E; Carcereny, E; Sala, M A; Bernabé, R; Provencio, M; Cuffe, S; Roschitzki-Voser, H; Ruepp, B; Rosell, R; ... (2022). Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO open, 7(3), p. 100507. Elsevier 10.1016/j.esmoop.2022.100507
Schmid, S; Jochum, W; Padberg, B; Demmer, I; Mertz, K D; Joerger, M; Britschgi, C; Matter, M S; Rothschild, S I; Omlin, A (2022). How to read a next-generation sequencing report-what oncologists need to know. ESMO open, 7(5), p. 100570. BMJ 10.1016/j.esmoop.2022.100570
Ribi, K; Kalbermatten, N; Eicher, M; Strasser, F (2022). Corrigendum to 'Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent': [ESMO Open volume 7 (2022) 100496]. ESMO open, 7(6), p. 100614. BMJ 10.1016/j.esmoop.2022.100614
Aeppli, S; Schmaus, M; Eisen, T; Escudier, B; Grünwald, V; Larkin, J; McDermott, D; Oldenburg, J; Porta, C; Rini, B I; Schmidinger, M; Sternberg, C N; Rothermundt, C; Putora, P.M. (2021). First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO open, 6(1), p. 100030. BMJ 10.1016/j.esmoop.2020.100030
Herbrand, Amanda; Schmitt, Andreas; Briel, Matthias; Diem, Stefan; Ewald, Hannah; Hoogkamer, Anouk; Joerger, Markus; Mc Cord, Kimberly; Novak, Urban; Sricharoenchai, Sirintip; Hemkens, Lars; Kasenda, Benjamin (29 July 2019). Contrasting Evidence to Reimbursement Reality for Off-label use 1 (OLU) of Drug Treatments in Cancer Care – Rationale and Design of 2 the CEIT-OLU-project (medRxiv). Cold Spring Harbor Laboratory 10.1101/19003152
Herbrand, Amanda Katherina; Schmitt, Andreas Michael; Briel, Matthias; Diem, Stefan; Ewald, Hannah; Hoogkamer, Anouk; Joerger, Markus; Mc Cord, Kimberly Alba; Novak, Urban; Sricharoenchai, Sirintip; Hemkens, Lars G; Kasenda, Benjamin (2019). Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO open, 4(6), e000596. BMJ 10.1136/esmoopen-2019-000596
Vogt, Alexia; Schmid, Sabine; Heinimann, Karl; Frick, Harald; Herrmann, Christian; Cerny, Thomas; Omlin, Aurelius Gabriel (2017). Multiple primary tumours: challenges and approaches, a review. ESMO open, 2(2), e000172. BMJ 10.1136/esmoopen-2017-000172
